Relapsing neuromyelitis optica: long term history and clinical predictors of death
- P Cabre1,
- A González-Quevedo2,
- M Bonnan1,
- A Saiz3,
- S Olindo1,
- F Graus3,
- D Smadja1,
- H Merle4,
- L Thomas5,
- J A Cabrera-Gomez6
- 1Department of Neurology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, French West Indies
- 2Cuban Multiple Sclerosis Society, Institute of Neurology and Neurosurgery, Havana, Cuba and National Institute of Neurology and Neurosurgery, Havana, Cuba
- 3Service of Neurology Hospital Clinic and Institut d’Invesigación Biomèdica August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- 4Department of Ophthalmology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, French West Indies
- 5Emergency Department, Pierre Zobda Quitman Hospital, Fort de France, Martinique, French West Indies
- 6Cuban Multiple Sclerosis Society and Multiple Sclerosis Clinic, Internacional Neurological Centre, Habana, Cuba and International Centre of Neurological Restoration (CIREN), Habana, Cuba
- Correspondence to P Cabre, Department of Neurology, Pierre Zobda Quitman Hospital, Fort de France, 97261 Martinique, French West Indies; Philippe.Cabre{at}chu-fortdefrance.fr
- Received 31 December 2007
- Revised 6 June 2008
- Accepted 9 July 2008
Abstract
Background: Relapsing neuromyelitis optica (RNMO) is an uncommon but devastating inflammatory disorder of the central nervous system. Long term history in a wide series of RNMO is required for better knowledge of the course of the disease and identification of patients at high risk of death.
Methods: Clinical features of patients with RNMO (88 women/eight men) obtained from the geographic Caribbean database (Cuba and French West Indies) were used to determine the progression of disability and to identify clinical predictors of death.
Results: Median age at onset of RNMO was 29.5 years (range 11–74). Median duration of disease was 9.5 years (1–40). Median relapse rate was 0.7 attack/patient/year (0.1–3). 66 patients experienced severe visual loss in at least one eye and 46 in both eyes. Median time from onset to unilateral and bilateral severe visual loss was 3 and 15 years, respectively. Median times to reach Kurtzke Disability Status Scale 3, 6 and 8 from onset of RNMO were 1, 8 and 22 years. There were 24 deaths (25%); within 5 years in 63% of cases. A higher attack frequency during the first year of disease (p = 0.009), blindness (p = 0.04) and sphincter signs at onset (p = 0.02) and lack of recovery of first attack (p = 0.003) were independently associated with a shorter time to death.
Conclusion: RNMO is a very rapidly disabling disease affecting primarily young women. This study has identified clinical features that predict a poor outcome. These findings suggest that early and aggressive immunotherapy might be warranted in RNMO.
Footnotes
-
▸ Supplementary data are published online only at http://jnnp.bmj.com/content/vol80/issue10
-
Funding NMO-IgG antibody was assessed by a grant support, in part from Fondo de Investigaciones Sanitarios, Madrid, Spain (PI060070; AS, FG) and U344 Inserm unit, Lyon, France (Romain Marignier MD).
-
Competing interests None.







